Donanemab-Azbt
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Comparison table: Amyloid beta-directed antibodies for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: March 24, 2026
Comparison table: Drugs for Alzheimer's disease dementia.
Journal: The Medical letter on drugs and therapeutics
Published: March 24, 2026
PET in Neurology: Imaging Pathology, Metabolism, and Disease Progression
Journal: Brain and nerve = Shinkei kenkyu no shinpo
Published: February 17, 2026
Elecsys - a second blood test for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: January 23, 2026
Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood-Brain Barrier in Targeted Treatment of Alzheimer's Disease.
Journal: Pharmaceutics
Published: December 27, 2025
Amyloid-Beta Immunotherapies for Alzheimer's Disease: Current Progress.
Journal: Current Alzheimer research
Published: November 23, 2025
In brief: Updates for lecanemab (Leqembi) for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: November 05, 2025
Donanemab (Kisunla) for the Slowing of Alzheimer Disease.
Journal: American family physician
Published: September 17, 2025
The tale of donanemab: God is in the details.
Journal: Journal of Alzheimer's disease : JAD
Published: September 03, 2025
In brief: A new donanemab (Kisunla) dosing regimen for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: August 12, 2025
Donanemab for Alzheimer's disease: from preclinical research to the clinical application.
Journal: Expert review of neurotherapeutics
Published: August 12, 2025
Last Updated: 06/30/2026